Drug Pipeline

Drugs in the pipeline for psoriasis and psoriatic arthritis

Drugs in the pipeline for psoriatic disease are being developed and tested, but haven't been approved by the U.S. Food and Drug Administration (FDA). Drugs must be tested in three phases of clinical trials before the FDA decides whether to approve them.

Explore our drug pipeline page to discover drugs being developed for psoriasis and psoriatic arthritis, learn about the differences between clinical trial phases, and see available clinical trial results. 

Drug Types

Biologics

Biologics

Biologic medicines, also known as biologics, are made from living sources (such as human, animal, or bacterial cells) in a laboratory. Biologics are typically used to treat moderate to severe psoriasis and psoriatic arthritis. They can be taken as a subcutaneous injection (a shot just under the skin) or through intravenous (IV) infusion, which is a slow drip of medicine into the vein. Many biologics work by reducing the activity of specific proteins that help drive inflammation, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-17, IL-12 and IL-23. They are used to treat moderate-to-severe psoriasis and psoriatic arthritis.

There is a different FDA approval process for biosimilars compared with other drugs. Biosimilar drugs are a type of biologic drug. Biosimilars are modelled after a biologic that has already been approved by the FDA, also known as the biosimilar’s reference product. Much of the scientific data that the FDA reviews when considering a biosimilar for approval comes from studies that compare the make-up of the biosimilar to the reference product. For that reason, clinical trial testing for biosimilars starts with Phase III. During Phase III trials of biosimilars, the biosimilar is compared with the reference product to study safety and effectiveness. Some biosimilars are tested specifically in people with psoriasis or psoriatic arthritis. But even if a biosimilar is not tested in psoriasis and psoriatic arthritis, it may still be approved as a psoriasis or psoriatic arthritis treatment if its reference product is approved for those diseases.
Oral Treatments

Oral Treatments

Oral treatments are taken by mouth and are usually used to treat moderate-to-severe psoriasis and psoriatic arthritis.  

Topicals

Topicals

Topicals are treatments that are applied directly to the skin, usually as a cream, ointment, or foam. Some are available only by prescription while others can be purchased over-the-counter. Topicals are commonly used to treat mild psoriasis. They can be used in combination with each other and with oral and biologic drugs.

Clinical Trials: Phase I

Drugs in development typically move through three phases of clinical trials on their way to obtaining approval by the FDA. Drug development starts with preclinical studies, in which the drug is analyzed through laboratory experiments and tested in animals. When a drug is ready to be tested in people, the first step is a phase I trial. The focus of phase I trials, which are usually conducted in a small number of people, is testing the drug for side effects and other safety concerns. Phase I trials also aim to determine the best dose for a drug. About 70 percent of drugs in phase I make it to phase II. 

 

Clinical Trials: Phase II

Phase II trials are the second stage of trials a drug goes through before it can be considered for approval by the FDA. Phase II trials involve more people than phase I trials do. In addition to evaluating the safety of the drug, phase II trials test how effectively a drug treats a certain condition. About one-third of drugs in phase II make it to phase III. NPF usually begins to share information about a drug in development when it makes it to phase II.

View All Drugs in Phase II
Legend: Psoriasis Psoriasitic Arthritis
Biologic (biosimilar)

Drug

ABT-122
anti-inflammatory

(IL-17 and TNF-alpha inhibitor)
Phase II
Psoriatic arthritis
Biologic
ABT-122 is a biologic being tested for psoriatic arthritis.
X
Biologic
ABT-122
Manufacturer
AbbVie
Current Trial Information Past Trials
Apo805K1
proprietary

(proprietary)
Phase II
Psoriasis
Oral
Apo805K1 is an oral treatment being tested in psoriasis.
X
Oral
Apo805K1
Manufacturer
ApoPharma
Current Trial Information Past Trials
Baricitinib
anti-inflammatory

(JAK1 and JAK2 inhibitor)
Phase II
Psoriasis
psoriatic arthritis
Oral
Baricitinib is an oral treatment that has been tested in psoriasis. It is scheduled to be tested in psoriatic arthritis in 2017.
X
Oral
Baricitinib
Manufacturer
Eli Lilly/Incyte
Current Trial Information Past Trials
Eucrisa (crisaborole)
anti-inflammatory

(phosphodiesterase-4 inhibitor)
Phase II
Psoriasis
Topical
Eucrisa is an ointment being tested in psoriasis. It has already been approved as a treatment for atopic dermatitis.
X
Topical
Eucrisa (crisaborole)
Therapeutic Approach
Eucrisa is applied as an ointment.
FDA Approved for
atopic dermatitis
Manufacturer
Pfizer
Current Trial Information Past Trials
FP187
anti-inflammatory

(fumaric acid)
Phase II
Psoriasis
Oral
FP187 is an oral treatment being tested in psoriasis.
X
Oral
FP187
Manufacturer
Forward-Pharma
Current Trial Information Past Trials
KD025
anti-inflammatory

(ROCK2 inhibitor)
Phase II
Psoriasis
Oral
KD025 is an oral treatment being tested in psoriasis.
X
Oral
KD025
Manufacturer
Kadmon Corporation
Current Trial Information Past Trials
Namilumab
anti-inflammatory

(granulocyte macrophage colony stimulating factor antagonist)
Phase II
Psoriasis
Biologic
Namilumab is a biologic being tested for psoriasis.
X
Biologic
Namilumab
Manufacturer
Takeda
Current Trial Information Past Trials
PH-10
skin cell inhibitor

(rose bengal)
Phase II
Psoriasis
Topical
PH-10 is a topical being tested as a treatment for psoriasis.
X
Topical
PH-10
Therapeutic Approach
PH-10 is applied as a gel.
Manufacturer
Provectus Biopharmaceuticals
Current Trial Information Past Trials
Prurisol
immune modulator

(IL-20 and PRINS inhibitor)
Phase II
Psoriasis
Oral
Prurisol is an oral treatment being tested in psoriasis.
X
Oral
Prurisol
Manufacturer
Cellceutix Corporation
Current Trial Information Past Trials
Risankizumab (BI 655066)
anti-inflammatory

(IL-23 inhibitor)
Phase II
Psoriatic arthritis
Biologic
Risankizumab is a biologic being tested for psoriasis and psoriatic arthritis.
X
Biologic
Risankizumab (BI 655066)
Manufacturer
Boehringer-Ingelheim and AbbVie
Current Trial Information Past Trials
SNA-120 (CT 327)
skin cell inhibitor

(TrkA kinase blocker)
Phase II
Psoriasis
Topical
SNA-120 is a topical being tested as a treatment for itch in psoriasis.
X
Topical
SNA-120 (CT 327)
Therapeutic Approach
SNA-120 is applied as a cream.
Manufacturer
Sienna Biopharmaceuticals
Current Trial Information Past Trials
Tofacitinib
anti-inflammatory

(JAK inhibitor)
Phase II
Psoriasis
Topical
Tofacitinib is a topical ointment being tested as a treatment for psoriasis. A tablet form of tofacitinib (an oral drug) is approved for the treatment of rheumatoid arthritis and is marketed as Xeljanz. The Xeljanz tablet is also being tested as a treatment for psoriatic arthritis.
X
Topical
Tofacitinib
Therapeutic Approach
Tofacitnib is applied as an ointment.
FDA Approved for
The tablet form, Xeljanz, is approved for the treatment of rheumatoid arthritis.
Manufacturer
Pfizer
Current Trial Information Past Trials
VTP-43742
anti-inflammatory

(ROR-gamma T inhibitor)
Phase II
Psoriasis
Oral
VTP-43742 is an oral treatment being tested in psoriasis.
X
Oral
VTP-43742
Manufacturer
Vitae Pharmaceuticals
Current Trial Information Past Trials
XP23829
anti-inflammatory

(fumaric acid)
Phase II
Psoriasis
Oral
XP23829 is an oral treatment being tested in psoriasis.
X
Oral
XP23829
Manufacturer
Dr. Reddy's Laboratories and XenoPort
Current Trial Information Past Trials
ZPL-389
anti-inflammatory

( histamine H4 receptor antagonist)
Phase II
Psoriasis
Oral
ZPL-389 is an oral treatment being tested in psoriasis.
X
Oral
ZPL-389
Manufacturer
Ziarco Pharma Ltd.
Current Trial Information Past Trials

Clinical Trials: Phase III

Phase III trials are the third and final stage of clinical trials that a drug goes through before it can be considered for approval by the FDA. During phase III trials, a drug is given to a large group of people to study safety and effectiveness. Phase III trials can also compare the drug to drugs that are already on the market for the same condition. About 25 percent of drugs in phase III are considered for FDA approval.

View All Drugs in Phase III
Legend: Psoriasis Psoriasitic Arthritis
Biologic (biosimilar)

Drug

ABP 710
Biosimilar for Remicade (infliximab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
ABP710 is a biosimilar for Remicade being tested in people with rheumatoid arthritis.
X
Biosimilar
ABP 710
Manufacturer
Amgen
Current Trial Information Past Trials
BCD-057
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
BCD-057 is a biosimilar for Humira being tested in people with psoriasis.
X
Biosimilar
BCD-057
Manufacturer
BIOCAD
Current Trial Information Past Trials
CHS-1420
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
CHS-1420 is a biosimilar for Humira being tested in people with psoriasis.
X
Biosimilar
CHS-1420
Manufacturer
Coherus Biosciences
Current Trial Information Past Trials
Cimzia (certolizumab pegol)
anti-inflammatory

(TNF-alpha inhibitor)
Phase III
Psoriasis
Biologic
Cimzia is a biologic approved for the treatment of several diseases, including psoriatic arthritis.
X
Biologic
Cimzia (certolizumab pegol)
Therapeutic Approach
Cimzia is taken as an injection.
FDA Approved for
Psoriatic arthritis, rheumatoid arthritis, anklyosing spondylitis, Crohn's disease
Manufacturer
UCB/Dermira
Current Trial Information Past Trials
GP2017
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
GP2017 is a biosimilar for Humira being tested in people with psoriasis or rheumatoid arthritis.
X
Biosimilar
GP2017
Manufacturer
Sandoz
Current Trial Information Past Trials
HD203
Biosimilar for Enbrel (etanercept)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
HD203 is a biosimilar for Enbrel being tested in people with rheumatoid arthritis.
X
Biosimilar
HD203
Manufacturer
Hanwha Chemical
Current Trial Information Past Trials
IDP-118
Combined vitamin D and corticosteroid treatment

(halobetasol propionate and tazarotene)
Phase III
Psoriasis
Topical
IDP-118 is a lotion being tested in psoriasis.
X
Topical
IDP-118
Therapeutic Approach
IDP-118 is applied as a lotion.
Manufacturer
Valeant Pharmaceuticals
Current Trial Information Past Trials
LAS41008
anti-inflammatory

(dimethyl fumarate)
Phase III
Psoriasis
Oral
LAS41008 is an oral treatment being tested in psoriasis.
X
Oral
LAS41008
Manufacturer
Almirall
Current Trial Information Past Trials
M51810
proprietary

(proprietary)
Phase III
Psoriasis
Topical
M51810 is a topical treatment being tested in psoriasis.
X
Topical
M51810
Therapeutic Approach
M51810 is applied as a topical.
Manufacturer
Maruho Co. Ltd.
Current Trial Information Past Trials
M923
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
M923 is a biosimilar for Humira being tested in people with psoriasis or rheumatoid arthritis.
X
Biosimilar
M923
Manufacturer
Momenta
Current Trial Information Past Trials
MC2-01 Cream (calcipotriene and betamethasone dipropionate)
moisturizer

(remittance maintenance)
Phase III
Psoriasis
Topical

Phase 3 trial to test safety, treatment to alleviate symptoms of PsO

X
Topical
MC2-01 Cream (calcipotriene and betamethasone dipropionate)
MSB11022
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
MSB11022 is a biosimilar for Humira being tested in people with psoriasis.
X
Biosimilar
MSB11022
Manufacturer
EMD Serono
Current Trial Information Past Trials
P-3073
Vitamin-D based treatment

(calcipotriene)
Phase III
Psoriasis
Topical
P-3073 is a nail solution being tested in nail psoriasis.
X
Topical
P-3073
Manufacturer
Polichem
Current Trial Information Past Trials
PF-06410293
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
PF-06410293 is a biosimilar for Humira being tested in people with rheumatoid arthritis.
X
Biosimilar
PF-06410293
Manufacturer
Pfizer
Current Trial Information Past Trials
PF-06438179
Biosimilar for Remicade (infliximab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
PF-06438179 is a biosimilar for Remicade being tested in people with rheumatoid arthritis.
X
Biosimilar
PF-06438179
Manufacturer
Pfizer
Current Trial Information Past Trials
Piclidenoson (CF101)
anti-inflammatory

(adenosine A3 receptor inhibitor)
Phase III
Psoriasis
Oral
Piclidenoson is an oral treatment being tested for psoriasis.
X
Oral
Piclidenoson (CF101)
Manufacturer
Can-Fite BioPharma
Current Trial Information Past Trials
Risankizumab (BI655066)
anti-inflammatory

(IL-23 inhibitor)
Phase III
Psoriasis
Biologic
Risankizumab is a biologic being tested for psoriasis and psoriatic arthritis.
X
Biologic
Risankizumab (BI655066)
SB2
Biosimilar for Remicade (infliximab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
SB2 is a biosimilar for Remicade being tested in people with rheumatoid arthritis.
X
Biosimilar
SB2
Manufacturer
Samsung Bioepis
Current Trial Information Past Trials
SB4
Biosimilar for Enbrel (etanercept

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
SB4 is a biosimilar for Enbrel being tested in people with rheumatoid arthritis.
X
Biosimilar
SB4
Manufacturer
Samsung Bioepis
Current Trial Information Past Trials
SB5
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Biosimilar
SB5 is a biosimilar for Humira being tested in people with rheumatoid arthritis.
X
Biosimilar
SB5
Manufacturer
Samsung Bioepis
Current Trial Information Past Trials
Taltz (ixekizumab)
anti-inflammatory

(IL-17 inhibitor)
Phase III
Psoriatic arthritis
Biologic
Taltz is a biologic that was approved for the treatment of psoriasis in 2016. It is also being tested as a treatment for psoriatic arthritis.
X
Biologic
Taltz (ixekizumab)
Therapeutic Approach
Taltz is taken as an injection.
FDA Approved for
Psoriasis
Manufacturer
Eli Lilly
Current Trial Information Past Trials
Tildrakizumab (MK-3222/SCH 900222)
anti-inflammatory

(IL-23 inhibitor)
Phase III
Psoriasis
Biologic
Tildrakizumab is a biologic being tested for psoriasis.
X
Biologic
Tildrakizumab (MK-3222/SCH 900222)
Xeljanz (tofacitinib)
anti-inflammatory

(JAK inhibitor)
Phase III
Psoriasis
psoriatic arthritis
Oral
Xeljanz is an oral treatment being tested in psoriatic arthritis. It is already FDA approved for the treatment of rheumatoid arthritis.
X
Oral
Xeljanz (tofacitinib)
Therapeutic Approach
Xeljanz is taken as a tablet.
FDA Approved for
rheumatoid arthritis, juvenile idiopathic arthritis
Manufacturer
Pfizer
Current Trial Information Past Trials

Clinical Trials: FDA-Approved

After the FDA approves a drug, it can be prescribed to patients. However, even though a drug is approved, it may still be tested in additional trials. These trials can involve long-term studies that evaluate the drug over several years, or they can involve comparing the drug with other drugs on the market. Sometimes an approved drug will be tested for other indications, such as for use in children or in other diseases. The list below includes drugs that have been FDA-approved for psoriatic disease in the last few years.

View All Drugs in FDA-Approved
Legend: Psoriasis Psoriasitic Arthritis
Biologic (biosimilar)

Drug

Cosentyx (secukinumab)
IL-17A inhibitor

(anti-inflammatory)
FDA-Approved
Psoriasis
Psoriatic Arthritis
Biologic

Approved for adults with PsO, PsA, AS

X
Biologic
Cosentyx (secukinumab)
Therapeutic Approach
injection
FDA Approved for
Psoriasis, psoriatic arthritis, ankylosing spondylitis
Cyltezo (adalimumab-adbm)
Biosimilar for Humira (adalimumab)

(TNF-alpha inhibitor)
FDA-Approved
Psoriasis
Psoriatic Arthritis
Biosimilar

Cyltezo is a biosimilar for Humira approved for the treatment of psoriasis and psoriatic arthritis.

X
Biosimilar
Cyltezo (adalimumab-adbm)
Manufacturer
Boehreinger Ingelheim
Current Trial Information Past Trials
Enbrel (etanercept)
TNF- Alpha blocker

(anti-inflammatory)
FDA-Approved
Psoriasis
Psoriatic Arthritis
Biologic

Moderate to severe Psoriatic arthritis, adult psoriatic arthritis.

X
Biologic
Enbrel (etanercept)
Orencia (abatecept)
immune suppressant

(prevents T-cell activation)
FDA-Approved
Psoriatic Arthritis
Biologic

Orencia is a biologic approved for the treatment of psoriatic arthritis. 

X
Biologic
Orencia (abatecept)
Therapeutic Approach
Orencia is taken as an injection.
FDA Approved for
rheumatoid arthritis, juvenile idiopathic arthritis
Manufacturer
Bristol-Myers-Squibb
Current Trial Information Past Trials
Otezla (apremilast)
phosphodiesterase 4 (PDE4) inhibitor

FDA-Approved
Psoriasis
Psoriatic Arthritis
Oral

Adults with PsA and/or Moderate to severe PsO

X
Oral
Otezla (apremilast)
Siliq (brodalumab)
anti-inflammatory

(IL-17 inhibitor)
FDA-Approved
Psoriasis
Biologic

Siliq is a biologic that was approved for the treatment of psoriasis in 2017. It is also being tested as a treatment for psoriatic arthritis.

X
Biologic
Siliq (brodalumab)
Therapeutic Approach
Siliq is taken as an injection.
FDA Approved for
Psoriasis
Manufacturer
Valeant Pharmaceuticals
Current Trial Information Past Trials
Simponi (golimumab)
anti-inflammatory

(TNF-alpha inhibitor)
FDA-Approved
Psoriatic Arthritis
Biologic

For adult use. 50 mg injection disposable.

X
Biologic
Simponi (golimumab)
Therapeutic Approach
injection
FDA Approved for
Psoriatic arthritis, ankylosing spondylitis
Manufacturer
Janssen
Current Trial Information Past Trials
Simponi Aria (golimumab)
anti-inflammatory

(TNF-alpha inhibitor)
FDA-Approved
Psoriatic Arthritis
Biologic

Adult use only

X
Biologic
Simponi Aria (golimumab)
Therapeutic Approach
infusion 2mg/kg
FDA Approved for
Psoriatic arthritis, ankylosing spondylitis
Manufacturer
Janssen
Current Trial Information Past Trials
Stelara (ustekinumab)
anti-inflammatory

(IL-12 and IL-23 inhibitor)
FDA-Approved
Psoriasis
Biologic

Stelara is a biologic that was approved for the treatment of psoriais in 2009 and for the treatment of and psoriatic arthritis in 2013. It has been approved in 2017 for treatment of adolescents (12+) with psoriasis.

X
Biologic
Stelara (ustekinumab)
Therapeutic Approach
Stelara is taken as an injection.
FDA Approved for
Psoriasis, psoriatic arthritis, ankylosing spondylitis
Tremfya (guselkumab)
anti-inflammatory

(IL-23 inhibitor)
FDA-Approved
Psoriasis
Biologic

Tremfya (guselkumab) is a biologic approved for the treatment of psoriasis and undergoing trials for the treatment of psoriatic arthritis.

X
Biologic
Tremfya (guselkumab)

Get Involved

Join a clinical trial.

Learn More

Find out what to expect from a clinical trial.

Compare

Explore psoriatic disease treatments already on the market.

Get In Touch

Let the Patient Navigation Center guide you on your journey to better health.